Register Login

KRYSTAL BIOTECH, INC. (KRYS)

(90% Positive) KRYSTAL BIOTECH, INC. (KRYS) Announces Enrollment Update for revenue Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 4, 2026, 11:07 a.m.

    📋 KRYSTAL BIOTECH, INC. (KRYS) - Clinical Trial Update

    Filing Date: 2026-05-04

    Accepted: 2026-05-04 07:07:01

    Event Type: Clinical Trial Update

    Event Details:

    KRYSTAL BIOTECH, INC. (KRYS) Announces Clinical Trial Update KRYSTAL BIOTECH, INC. (KRYS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: revenue, designation
    • Diseases/Conditions: VYJUVEK
    • Collaboration: DocumentKrystal Biotech
      • anticipated in 2H 2026
      • anticipated in 2026

    🔬 Clinical Development Pipeline (KRYSTAL BIOTECH, INC.):

    Product Type Development Stage Therapeutic Area Source
    Chemotherapy Drug Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    Chemotherapy DRUG Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    KB304 Other Phase PHASE1 Wrinkles in Decolletage ClinicalTrials.gov
    Placebo gel Other Phase PHASE1 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    KB707 Other Phase PHASE1 Cancer ClinicalTrials.gov
    KB803 Other Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    KB801 Other Phase PHASE1 Neurotrophic Keratitis ClinicalTrials.gov
    LY2456302 Other Phase PHASE1 Anxiety Disorders ClinicalTrials.gov
    KB105 Other Phase PHASE1 TGM-1 Related Autosomal Recessive Congenital Ichthyosis ClinicalTrials.gov
    Topical beremagene geperpavec Other Phase PHASE1 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    Placebo Other Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    KB407 (Nebulization) Other Phase PHASE1 Cystic Fibrosis ClinicalTrials.gov
    Open Label Topical Beremagene Geperpavec (B-VEC) Other Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    Irinotecan Other Phase PHASE1 Pilomyxoid Astrocytoma ClinicalTrials.gov
    Bevacizumab Other Phase PHASE1 Pilomyxoid Astrocytoma ClinicalTrials.gov
    Temozolomide Other Phase PHASE1 Pilomyxoid Astrocytoma ClinicalTrials.gov
    Carboplatin Other Phase PHASE1 Pilomyxoid Astrocytoma ClinicalTrials.gov
    Vincristine Other Phase PHASE1 Pilomyxoid Astrocytoma ClinicalTrials.gov
    Mebendazole Other Phase PHASE1 Pilomyxoid Astrocytoma ClinicalTrials.gov
    0.9% Normal Saline (NS) Other Phase PHASE1 Wrinkles in Decolletage ClinicalTrials.gov
    KB301 Other Phase PHASE1 Skin Roughness ClinicalTrials.gov
    KEYTRUDA ®( Pembrolizumab) Other Phase PHASE1 Cancer ClinicalTrials.gov
    Opdualag Other Phase PHASE1 Cancer ClinicalTrials.gov
    KB408 (Nebulization) Other Phase PHASE1 Alpha 1-Antitrypsin Deficiency ClinicalTrials.gov
    Device: Stimulation -ON Active Control Device Approved Bipolar II Disorder ClinicalTrials.gov
    Device: Stimulation-OFF Device Approved Bipolar II Disorder ClinicalTrials.gov
    Device: Stimulation-ON Device Approved Bipolar II Disorder ClinicalTrials.gov
    Docetaxel Other Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    Pembrolizumab (KEYTRUDA®) Other Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    Sham Repetitive Transcranial Magnetic Stimulation (rTMS) Other Approved Schizophrenia ClinicalTrials.gov
    Repetitive Transcranial Magnetic Stimulation (rTMS) Other Approved Schizophrenia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: KRYSTAL BIOTECH, INC.
    • Ticker Symbol: KRYS

Search

News categories